0.1139

1.96% -0.00228

After Hours: .1122 -0.00172 -1.51%

NLS Pharmaceutics Ltd (NLSP)

Overview News Price History Why NLSP Down? Discussions Forecast

NLS Pharmaceutics Ltd stock is currently priced at $0.1139, with a 24-hour trading volume of 458.87K. It has seen a -1.96% decreased in the last 24 hours and a -24.50% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.1196 pivot point. If it approaches the $0.1119 support level, significant changes may occur.

Previous Close:

$0.1162

Open:

$0.12

24h Volume:

458.87K

Market Cap:

$4.94M

Revenue:

Net Income/Loss:

$-15.47M

P/E Ratio:

-0.1356

EPS:

-0.84

Net Cash Flow:

$-13.51M

1W Performance:

-10.79%

1M Performance:

-24.50%

6M Performance:

-73.05%

1Y Performance:

-87.55%

1D Range:

$0.112

$0.123

52W Range:

$0.1112

$1.53

NLS Pharmaceutics Ltd Stock (NLSP) Company Profile

Name

NLS Pharmaceutics Ltd

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

41 44 512 21 50

Address

The Circle 6, Zurich

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NLSP's Discussions on Twitter

NLS Pharmaceutics Ltd Stock (NLSP) Latest News

NLS Pharmaceutics Ltd (NLSP)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News

US Post News

NLS Pharmaceutics Ltd (NLSP) Stock: A Year of Market Fluctuations - The InvestChronicle

The InvestChronicle

NLS Pharmaceutics Ltd (NLSP) Stock: A Year of Highs and Lows - The InvestChronicle

The InvestChronicle

Closing Bell Recap: NLS Pharmaceutics Ltd (NLSP) Ends at 0.14, Reflecting a -15.16 Downturn – DWinneX - The Dwinnex

The Dwinnex

NLS Pharmaceutics Announces CMO Resignation - TipRanks.com - TipRanks

TipRanks

NLS Pharmaceutics Ltd (NLSP) deserves deeper analysis – US Post News - US Post News

US Post News

NLS Pharmaceutics Ltd Stock (NLSP) Financials Data

NLS Pharmaceutics Ltd (NLSP) Net Income 2024

NLSP net income (TTM) was -$15.47 million for the quarter ending June 30, 2023, a -148.17% decrease year-over-year.

NLS Pharmaceutics Ltd (NLSP) Cash Flow 2024

NLSP recorded a free cash flow (TTM) of -$13.51 million for the quarter ending June 30, 2023, a -36.06% decrease year-over-year.

NLS Pharmaceutics Ltd (NLSP) Earnings per Share 2024

NLSP earnings per share (TTM) was -$0.50 for the quarter ending June 30, 2023, a +12.86% growth year-over-year.

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.